These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9951955)

  • 41. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.
    Pecherstorfer M
    Expert Opin Pharmacother; 2004 Nov; 5(11):2341-50. PubMed ID: 15500381
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bisphosphonates in the treatment of metabolic bone diseases.
    Rodan GA; Balena R
    Ann Med; 1993 Aug; 25(4):373-8. PubMed ID: 8217103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zoledronic acid.
    Cheer SM; Noble S
    Drugs; 2001; 61(6):799-805; discussion 806. PubMed ID: 11398911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.
    Cundy T; Wheadon L; King A
    J Bone Miner Res; 2004 May; 19(5):703-11. PubMed ID: 15068492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
    Bauss F; Bergström B
    Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative tolerability of drug therapies for hypercalcaemia of malignancy.
    Zojer N; Keck AV; Pecherstorfer M
    Drug Saf; 1999 Nov; 21(5):389-406. PubMed ID: 10554053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
    Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B
    Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
    Adami S; Zamberlan N; Mian M; Dorizzi R; Rossini M; Braga B; Gatti D; Bertoldo F; Locascio V
    Bone Miner; 1994 May; 25(2):75-82. PubMed ID: 8086853
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
    Reginster JY; Wilson KM; Dumont E; Bonvoisin B; Barrett J
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5018-24. PubMed ID: 15972582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
    Sakurai T
    Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ibandronate: a clinical pharmacological and pharmacokinetic update.
    Barrett J; Worth E; Bauss F; Epstein S
    J Clin Pharmacol; 2004 Sep; 44(9):951-65. PubMed ID: 15317823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Dunn CJ; Fitton A; Sorkin EM
    Drugs Aging; 1994 Dec; 5(6):446-74. PubMed ID: 7858370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.
    Ravn P; Christensen JO; Baumann M; Clemmesen B
    Bone; 1998 May; 22(5):559-64. PubMed ID: 9600792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current and future directions in medical therapy: hypercalcemia.
    Body JJ
    Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis.
    Riis BJ; Ise J; von Stein T; Bagger Y; Christiansen C
    J Bone Miner Res; 2001 Oct; 16(10):1871-8. PubMed ID: 11585352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pamidronate.
    Kellihan MJ; Mangino PD
    Ann Pharmacother; 1992 Oct; 26(10):1262-9. PubMed ID: 1421653
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone.
    Reid IR; Wattie D; Gamble GD; Kalluru R; Cundy T
    Calcif Tissue Int; 2017 Mar; 100(3):250-254. PubMed ID: 27866237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.